, Tracking Stock Market Picks
Enter Symbol:
Biocryst Pharmaceuticals, Inc. (BCRX) [hlAlert]

down 14.00 %

Biocryst Pharmaceuticals, Inc. (BCRX) downgraded to Underperform by BofA/Merrill

Posted on: Tuesday,  Jan 28, 2014  8:25 AM ET by BofA/Merrill

BofA/Merrill rated Underperform Biocryst Pharmaceuticals, Inc. (NASDAQ: BCRX) on 01/28/2014, when the stock price was $9.64. Since
then, Biocryst Pharmaceuticals, Inc. has gained 16.29% as of 01/25/2016's recent price of $11.21.
If you would have followed this BofA/Merrill's recommendation on BCRX, you would have lost 14% of your investment in 727 days.

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/28/2014 8:25 AM Sell
as of 10/17/2014
1 Week down  -11.02 %
1 Month down  -2.47 %
3 Months down  -8.12 %
1 YTD down  -20.12 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/12/2013 8:25 AM Hold
7/31/2013 8:25 AM Sell
2/4/2013 10:25 AM Hold

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy